Education
About Us
Working with TipRanks
Follow Us
Mentice AB (SE:MNTC)
:MNTC
Top Page
Mentice AB
(Frankfurt:MNTC)
51Neutral
Mentice AB (MNTC) vs. S&P 500 (SPY)
Market Cap
kr502.43M
Dividend YieldN/A
Average Volume (3M)3.99K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth6.11%
EPS Growth-553.72%
CountrySE
Employees109
SectorTechnology
Sector Strength44
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.72
Shares Outstanding25,568,850
10 Day Avg. Volume1,963
30 Day Avg. Volume3,986
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Mentice AB Business Overview & Revenue Model
Company DescriptionMentice AB (MNTC) is a global leader in medical simulation solutions, specializing in the development of high-fidelity virtual reality-based training systems for healthcare professionals. The company focuses primarily on endovascular procedures, offering products that help medical practitioners enhance their skills and improve patient outcomes. With a strong emphasis on innovation, Mentice provides a range of simulators designed to replicate real-life surgical scenarios, thus aiding in the education and training of surgeons and medical students worldwide.
How the Company Makes MoneyMentice AB generates revenue through the sale of its medical simulation solutions, which include high-tech simulators for various endovascular procedures. The company's primary revenue streams are derived from direct sales to healthcare institutions, including hospitals, medical universities, and training centers. Additionally, Mentice offers subscription-based software licenses and maintenance contracts, providing ongoing technical support and updates for their products. The company also partners with medical device manufacturers to develop integrated training solutions, which can further contribute to its revenue. These collaborations enable Mentice to offer customized training modules that complement specific medical devices, thereby enhancing its value proposition to customers.
Mentice AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 274.55M | 273.61M | 217.95M | 185.06M | 137.50M | 149.37M | Gross Profit |
| 177.95M | 236.38M | 188.94M | 149.92M | 104.11M | 126.85M | EBIT |
| -21.17M | -679.00K | -22.67M | -18.51M | -31.59M | -27.81M | EBITDA |
| 6.82M | 28.87M | 266.00K | 1.44M | -3.90M | -13.63M | Net Income Common Stockholders |
| -23.28M | -2.82M | -30.66M | -29.19M | -13.09M | -20.60M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 57.51M | 59.12M | 47.28M | 12.70M | 48.75M | 48.04M | Total Assets |
| 298.99M | 322.53M | 332.98M | 261.90M | 245.27M | 187.14M | Total Debt |
| 7.94M | 9.56M | 16.68M | 14.70M | 11.51M | 15.45M | Net Debt |
| -49.56M | -49.56M | -30.61M | 2.01M | -37.24M | -32.59M | Total Liabilities |
| 163.37M | 163.55M | 170.34M | 125.02M | 82.02M | 62.38M | Stockholders Equity |
| 135.62M | 158.97M | 162.63M | 136.89M | 163.25M | 124.77M |
| Cash Flow | Free Cash Flow | ||||
| -19.70M | 29.53M | 1.85M | -31.03M | 5.20M | -41.25M | Operating Cash Flow |
| -3.75M | 36.52M | 14.91M | -5.13M | 30.53M | -37.28M | Investing Cash Flow |
| -15.94M | -16.18M | -32.28M | -25.90M | -24.97M | -3.97M | Financing Cash Flow |
| -7.50M | -7.05M | 48.99M | -5.78M | -3.98M | 71.30M |
Mentice AB Technical Analysis
Negative
18.50
Price Trends
21.46
Negative
23.33
Negative
25.67
Negative
Market Momentum
-0.96
Positive
39.58
Neutral
67.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Negative. The current price of 18.5 is below the 20-day moving average (MA) of 20.28, below the 50-day MA of 21.46, and below the 200-day MA of 25.67, indicating a bearish trend. The MACD of -0.96 indicates Positive momentum. The RSI at 39.58 is Neutral, neither overbought nor oversold. The STOCH value of 67.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MNTC.
Mentice AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr997.81M | 17.66 | 18.74% | ― | 10.46% | 22.82% | |
58 Neutral | $9.99B | 10.12 | -6.46% | 3.10% | 7.47% | -11.60% | |
51 Neutral | kr502.43M | ― | -12.29% | ― | 6.11% | -553.72% | |
47 Neutral | kr826.48M | ― | -1.05% | ― | 16.17% | 82.09% | |
46 Neutral | kr239.34M | ― | -102.63% | ― | -0.61% | 54.19% | |
45 Neutral | kr1.03B | ― | -8.64% | ― | 19.91% | 78.46% | |
44 Neutral | kr285.45M | ― | -12.79% | ― | -6.43% | -323.52% |
* Technology Sector Average
Performance Comparison
SE:MNTC
Mentice AB
19.00
-17.70
-48.23%
SE:ACARIX
Acarix AB
0.24
<0.01
1.70%
SE:BACTI.B
Bactiguard Holding AB
30.20
-38.00
-55.72%
SE:CRAD.B
C-Rad AB Class B
29.45
-9.05
-23.51%
SE:INTEG.B
Integrum AB Class B
13.46
-47.94
-78.08%
SE:SEDANA
Sedana Medical AB
8.32
-6.24
-42.86%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.